Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
UK Biobank, GSK and Regeneron announce largest gene sequencing initiative on world’s most detailed health database to improve drug discovery and disease diagnosis
Groundbreaking UK/US initiative will deliver first data within a year
Read more -
GSK’s MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
MUSCA study shows asthma patients achieved improvements in their health-related quality of life a...
Read more -
GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen
GSK today announced the closure of an agreement with Aspen aligned with GSK’s strategy of simplif...
Read more -
Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma
Positive headline results from a non-inferiority lung function study
Read more -
ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment
Headline results were announced in December 2016 and detailed study results are being presented a...
Read more -
Results announcement for the fourth quarter 2016
View full Q4 2016 Results (PDF)
Read more -
Abbas Hussain to leave GSK
Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company.
Read more -
Luke Miels appointed President, Global Pharmaceuticals, GSK
Luke Miels has been appointed President, Global Pharmaceuticals, GSK.
Read more -
GSK confirms closure of agreement to divest non-core assets to Aspen
GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmac...
Read more -
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention
First injectable to be studied for efficacy in pre-exposure prophylaxis
Read more -
GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma
The start of a phase III study investigating the effects of once-daily closed triple combination ...
Read more -
GSK announces Board changes
the creation of a new Board committee and a number of changes to the membership of the Board and ...
Read more -
ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen
First phase III studies to show efficacy of two-drug regimen as maintenance therapy
Read more -
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of H...
Read more -
GSK submits regulatory application in Japan for belimumab in systemic lupus erythematosus
Belimumab is a human monoclonal antibody that selectively targets B-lymphocyte stimulator an impo...
Read more -
GSK opens new global vaccines R&D center in Rockville, MD, USA
New state-of-the-art facility will house 450 scientists and support staff, creating up to 200 new...
Read more -
Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him
After seven years as CEO of ViiV Healthcare, Dr Dominique Limet will step down at the end of Marc...
Read more -
Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
Relvar is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting b...
Read more -
GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
The filing by GSK of a regulatory submission closed triple combination therapy FF/UMEC/VI 100/62....
Read more -
GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Tthe regulatory submission of a MMA to the EMA seeking approval for ShingrixTM.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
